RAPT: Rega marang dodolan RAPT Therapeutics
The valuation of RAPT Therapeutics, Inc. (RAPT) is based on future patent protection for immune therapies, which allows the company to exercise pricing power. The price-to-sales ratio illustrates valuation deviations from the norm, where the value of 810.70 expresses the metric level. The current balance sheet is supported by prudent funding of clinical trials, while R&D development in oncology and inflammation provides growth potential.
RAPT Therapeutics, Inc. (RAPT) - rincian metrik lan laporan keuangan
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Utang Agregat marang Ekuitas RAPT Therapeutics, Inc.|RAPT - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal rapt.com|RAPT - Gunggung utang perusahaan|Rasio utang marang aset resik RAPT|RAPT - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak RAPT Therapeutics|Rasio jangkoan perantara rapt.com
- informasi bathi lan kelipatan valuasi:
RAPT - Bathi resik|Bathi resik sing dikarepake RAPT Therapeutics, Inc.|RAPT - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi RAPT Therapeutics Inc.|RAPT - Pangali PEG|Pangali EV/EBITDA RAPT|RAPT - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben siji saham sajrone 12 wulan pungkasan RAPT Therapeutics|RAPT - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan rapt.com|RAPT - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep RAPT Therapeutics, Inc.
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:RAPT Therapeutics Inc., RAPT
For RAPT Therapeutics, Inc. (RAPT), which operates in the high-risk immunological development segment, the company's P/S ratio serves as an indicator of market expectations regarding the commercialization of its patented molecules. This ratio is calculated as the relationship between market capitalization and annual revenue, allowing investors to determine the extent of the premium paid for current sales and assess the asset's stability compared to its historical values.
Karo sapa RAPT Therapeutics, Inc. saingan
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PTGX (Protagonist Corp)|IMVT: Multiplikator P/S|kiniksa.com (KNSA) - Multiplikator P/S|Rasio rega marang pendapatan Grifols|Adaptive Biotech - Rasio rega marang dodolan|Kapitalisasi marang pendapatan CLDX (Celldex)|Kapitalisasi marang volume dodolan AUPH|BioCryst - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan VERA|DNTH: Kapitalisasi marang pendapatan|Pharvaris NV - Kapitalisasi marang volume dodolan|ABCL: Multiplikator P/S|Tourmaline - Rasio kapitalisasi pasar marang pendapatan|PGEN (Precigen, Inc.) - Multiplikator P/S|Rega marang dodolan pharming.com PHAR|Rasio rega marang pendapatan Nektar Therapeutics Inc. (NKTR)|UPB (Upstream Bio, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ZBIO (Zenas Biopharma, Inc.)|Multiplikator P/S Immunome Bio IMNM|GOSS - Rasio rega marang pendapatan|Rasio rega marang dodolan KALV|SEPN: Multiplikator P/S|Rega marang dodolan Pieris Pharma (PVLA)|Kapitalisasi marang pendapatan SVRA|Multiplikator P/S Rigel Corp|Kapitalisasi marang pendapatan ANAB (AnaptysBio, Inc.)|Kapitalisasi marang volume dodolan ATXS|Multiplikator P/S ENGN (enGene)|Koefisien rega marang pendapatan Aerovate Therapeutics, Inc. (JBIO)|Aclaris - Multiplikator P/S|Kyverna Therapeutics, Inc (KYTX) - Kapitalisasi marang pendapatan|Tiziana Life Sciences (TLSA) - Rasio rega marang pendapatan|CABA - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan VTYX|THTX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S AVTX|Koefisien rega marang pendapatan Eledon Pharmaceuticals, Inc|Rasio rega marang pendapatan Agenus AGEN|CLYM: Rasio kapitalisasi marang pendapatan|Zura Bio - Multiplikator P/S|aTyr Pharma Inc (ATYR) - Kapitalisasi marang pendapatan|ADAG (adagene.com) - Kapitalisasi marang pendapatan|IMA - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Shattuck Labs Inc|EQ: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S CNTB|Multiplikator P/S immunic-therapeutics.com (IMUX)|Rasio rega marang pendapatan Atara Bio ATRA|IFRX (InflaRx NV) - Rasio rega marang dodolan|XFOR: Kapitalisasi marang pendapatan|Adicet Bio - Kapitalisasi marang volume dodolan|celularity.com (CELU) - Rasio rega marang pendapatan|Rasio rega marang dodolan INMB (INmune Bio Inc)|BRNS (Barinthus Bio) - Multiplikator P/S|KZR: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S SABS|Multiplikator P/S akaritx.com (AKTX)|Rasio rega marang pendapatan Enlivex Therapeutics Ltd. ENLV|Rasio kapitalisasi pasar marang pendapatan QTTB|GOVX - Rasio rega marang pendapatan|Edesa Biotech Corp (EDSA) - Kapitalisasi marang pendapatan|IBIO: Multiplikator P/S|Carisma Therapeutics Inc. (CARM) - Multiplikator P/S|Kapitalisasi marang pendapatan XTLB|BOLT: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HCWB|Koefisien rega marang pendapatan aptevotherapeutics.com|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|ADTX - Kapitalisasi marang pendapatan|GRI - Rasio rega marang pendapatan|XORTX Therapeutics Inc (XRTX) - Kapitalisasi marang pendapatan|HIND (ReShape Lifesciences) - Kapitalisasi marang pendapatan|Revelation Biosciences Corp (REVB) - Multiplikator P/S|Rasio rega marang pendapatan Indaptus Therapeutics|Rasio kapitalisasi marang pendapatan SCNI (scinai.com)|Multiplikator P/S CALI|AFMD - Rega marang dodolan|Rasio rega marang pendapatan Allakos ALLK|Rasio kapitalisasi pasar marang pendapatan HOOK|IGM Bio - Multiplikator P/S|ITOS - Multiplikator P/S|Ocean Biomedical (OCEA) - Rasio rega marang pendapatan|Rasio rega marang dodolan TCBP (TC BioPharm (Holdings) Plc)|Kapitalisasi marang pendapatan THRD
